A new class of polyoxoniobate complex has been synthesized and characterized as a novel anticancer agent for photodynamic therapy. The complex inhibits the growth of chronic myelogenous leukemia cells with an IC
50 value of 30 μM, in the dark. However, upon exposure to light (365 nm) there is a fivefold increase in the cytotoxic activity. Light radiation activate the complex with the formation of radical species capable of interacting with DNA according to our experimental and theoretical data.A new class of polyoxoniobate complex has been synthesized and characterized as a novel anticancer agent for photodynamic therapy.
In this work, we prepared a photosensitive peroxoniobium complex presenting a balance with an active radical phase when illuminated with radiation of 365 nm. A versatile niobium species of amorphous structure was obtained by the reaction of niobium ammonium oxalate with ammonium hydroxide up to pH 7. The material obtained, a niobium oxyhydroxide (NbO
2(OH)) (white solid),
1,2 can be modified with the generation of NbO
2(OH)O
2˙
− peroxo groups (yellow solid).
3 The yellow compound is formed by treatment with H
2O
2. The absorption radiation in the visible region due to the charge transfer transition between the peroxo group and the niobium is shown in .
Open in a separate windowUV-Vis profile of the catalysts.This complex with the radical as an intermediate is favored in the presence of visible and UV radiation. This property is of interest for photodynamic therapy of cancer (PDT), which involves the exposure of malignant cells containing a photosensitizer molecule to light irradiation, in the presence of oxygen species. The photoactivated drug produces reactive oxygen species that initiate a series of events, resulting in cell death. Selective light activation allows a preferential tumor destruction in comparison to healthy tissues.
4 Several metal complexes exhibit photocytotoxicity under UV or visible light,
5,6 but data about niobium compounds are very scarce in the literature.
7The polyoxoniobate, generated from niobium oxyhydroxide described here can be very active in the treatment of diseased cells when illuminated with visible or UV radiation due to its light absorption capacity because of the peroxo groups formed. The peroxoniobium complex has some advantages, such as ease synthesis and in mild conditions, high solubility, low activity under light off, and resistance to inactivation by thiol reagents. Moreover, it is nontoxic
8 and does not employ noble metals like most of the compounds proposed in the literature. Actually, niobium oxide was tested as a bone implant component and showed absence of inflammatory cells or degeneration of the osteoblasts without any sign of damage to the preexisting bone tissue, showing compatibility with the bone tissue.
9–11The innovative part in the process of obtaining the polyoxoniobate complex presented in this work consists in the leaching of the complex when treating the niobium oxyhydroxide with H
2O
2. With the treatment, a yellow solid and a leached yellow liquid is obtained, which is the complex containing peroxoniobium in its structure, sensitive to the UV-Vis radiation generating radical species. This species generated with the leaching at neutral pH presents high negative charge and a kinetic volume of 223 nm. The XRD of the lyophilized polyoxoniobate indicated strong amorphous character. However, the polyoxoniobate is known to form well defined polyoxometalates such as Lindqvist ([Nb
6O
19]
8−) and decaniobate ([Nb
10O
28]
6−). shows a comparison between the experimental and PBE/LANL2DZ/aug-cc-pVDZ DFT IR spectra. It is clear that the pattern of the decaniobate structure is closer to the experimental spectrum. One should keep in mind that DFT frequencies are normally 10% underestimated with respect to the experimental values. The broader absorption below 600 cm
−1 can be attributed to the interaction between different decaniobate structures forming the amorphous solid. The calculated peaks at 710, 760 and 860 cm
−1 are related to the experimental peaks of 800, 870 and 910 cm
−1 indicating that decaniobate is the local arrangement of the polyoxoniobate complex.
Open in a separate windowInfrared spectra for experimental procedures, Lindqvist and decaniobate structures (simulated). The line shape chosen was Lorentzian and the half-width is about 20.The generation of reactive oxygen under radiation was confirmed by the reaction of the complex with an organic dye, which was monitored by UV-Vis spectroscopy (). The spectrum of the dye solution shows the characteristic peak of the methylene blue (MB) at 663 nm (black trace). It can be clearly seen that in the presence of the peroxoniobium complex and radiation (365 nm) the signal decreased indicating the reaction of the peroxoniobium complex with the dye (blue trace). In the absence of light, there is no decrease in the signal related to the dye, indicating the need of the radiation to activate the oxidation action of the peroxoniobium complex. The equilibrium in which the radical species forms it is not necessary to use a photosensitizer agent, such as porphyrins.
4 A further investigation was carried out by
31P NMR (Fig. S1
†) using guanosine as model molecule able to react with the peroxoniobium complex. The
31P NMR spectrum shown in Fig. S1-a
† corresponds to 5-GMP and revealed that the phosphorus atom in the structure exhibits a chemical shift at
δ 5.93. When 5-GMP and the polyoxoniobate are in contact, no significant changes are observed in the
31P spectrum, only a small displacement of the phosphorus signal to
δ 5.90 (Fig. S1-b
†). However, when the 5-GMP and polyoxoniobate mixture is submitted to radiation (Fig. S1-c
†), an interaction between the compounds occurs, giving rise to a new species that presents a different chemical shift in the P spectrum (
δ 5.27).
Open in a separate windowUV-Vis profile of the reaction of the Nb complex with the organic dye (10 mg L
−1).The effect of the peroxoniobium on the growth of K562 cells was evaluated after 4 h of incubation. The compound inhibits K562 cell growth in a concentration-dependent manner, with an IC
50 of 30.0 ± 1.5 μmol L
−1. Ammonium niobate(
v) oxalate was also tested and it has no effect on K562 cells up to 100 μM. The cytotoxic activity of polyoxoniobate increases by 5 times upon 5 min of UV-A light irradiation, with an IC
50 value of 6.2 ± 0.4 μmol L
−1 (). The higher activity, when exposed to light, associated to the low toxicity of niobium compounds place the peroxoniobium complex as a candidate for photodynamic therapy.
Open in a separate windowPhotocytotoxic effect of the peroxoniobium complex. K562 cells were incubated for 4 h in the presence of different complex concentrations, in the dark (black bars) and after 5 min of UV-A light exposure (red bars). The values are the average of three independent experiments.There are few reports in the literature about the cytotoxic activity of niobium compounds. A peroxo niobium complex with ascorbic acid (K
3[Nb(Asc)(O
2)
3]) is moderately active in HL60 human leukemia cells but not in K562 human myelogenous leukemia cells.
12 A tetrameric Nb28-containing cluster inhibits the growth of the human breast cancer MCF-7 cells line with an IC
50 value of 5.21, after 48 h of incubation.
13Methylene blue (MB) is one of the main photosensitizing agents used in PDT due to its good tissue penetration and low cytotoxicity.
14 It is active in several types of tumors upon irradiation with red laser light.
15 This fact allied to the ability of the peroxoniobium compound to interact with MB () prompted us to investigate its effect in the MB photocytotoxicity. We have first checked that exposure to UV-A light did not affect the cytotoxicity of MB in K562 cells (